03 Jun Risk of Pancreatic Cancer May Be Increased by Performance Enhances Like Cardarine
MedicalResearch.com Interview with:
Imad Shureiqi, MD, MS
Professor, Division of Hematology and Oncology
Department of Internal Medicine
Rogel Cancer Center
Ann Arbor, MI, 48109
MedicalResearch.com: What is the background for this study?
Response: Pancreatic ductal adenocarcinoma is a highly lethal form of cancer with rising occurrence, and strategies to prevent and treat the disease are urgently needed. Most cases of pancreatic cancer arise from pre-cancerous lesions called pancreatic intraepithelial neoplasia (PanIN); about 55-80% of adults over forty are estimated to have these low-grade pre-cancerous silent pancreatic lesions. But critical factors that promote the progression of pancreatic pre-cancerous lesions to pancreatic cancer remain poorly defined, especially those easy to target.
Findings from this publication indicate that people who have silent PanIN pre-cancerous lesions, even those that are low-grade, could increase their risk of PanIN progression into pancreatic cancer by consuming activators of a nuclear lipid receptor called peroxisome proliferator-activated receptor-delta (PPARδ). PPARδ activators can be natural substances, such certain fatty acids like palmitic and arachidonic acid in high-fat diets, or synthetic ones, like Cardarine (GW501516).
MedicalResearch.com: What are the main findings?
Response: Findings from this publication indicate that people who have silent PanIN pre-cancerous lesions, even those that are low-grade, could increase their risk of PanIN progression into pancreatic cancer by consuming activators of a nuclear lipid receptor called peroxisome proliferator-activated receptor-delta (PPARδ). PPARδ activators can be natural substances, such certain fatty acids like palmitic and arachidonic acid in high-fat diets, or synthetic ones, like Cardarine (GW501516).
Synthetic PPARδ are found in exercise supplements aimed to boost physical performance and endurance. For example, GW501516 was originally designed by pharmaceutical companies to encourage the body to use more fat and treat non-cancerous conditions like obesity and hyperlipemia. Pharmaceutical development of GW501516 and other similar potent PPARδ agonists for medical use has long been discontinued given their potential pro-cancerous side effects. Though studies on how PPARδ affects colorectal cancer date back to 1999, and pharmaceutical companies have halted synthetic PPARδ ligand development, unregulated internet outlets still sell substances like Cardarine. Ads are largely marketed to young people, claiming it will help them build muscle endurance and burn fat.
MedicalResearch.com: What should readers take away from your report?
Response: This new information should alert individuals to the potential serious health risks from using synthetic PPARδ agonists such as Cardarine. Limiting exposure to high-fat diets could also be considered for age groups with a high prevalence of pre-cancerous pancreatic lesions.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: Future development of effective agents to block PPARδ activation could be a new approach to prevent the progression of pre-cancerous lesions into pancreatic cancer.
MedicalResearch.com: Is there anything else you would like to add?
Response: Thank you for the opportunity to share our published information.
Liu, Y., Deguchi, Y., Wei, D. et al. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARδ. Nat Commun 13, 2665 (2022). https://doi.org/10.1038/s41467-022-30392-7
High fat diet, unregulated athletic exercise endurance enhancers linked to risk of pancreatic cancer (uofmhealth.org)
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. Some links may be sponsored and no links are warranted or endorsed by MedicalResearch.com or its parent company, Eminent Domains Inc. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.